LBX Pharmacy Chain Joint Stock Company (603883) Fair Value & Analysis
Healthcare · CN · Market cap 9.7B CNY
Fair value as of: Aug 13, 2026
From 26 valuation models · updated today
Share price +10.1% over the past month.
A solid business, but screening 22% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥13.21). The favourable scenario is already priced in.
- Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ¥10.70 – ¥40.21 · fair‑value band ¥7.92 – ¥13.21 · the ¥13.58 price screens above the ¥10.57 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
LBX Pharmacy Chain Joint Stock Company (603883) currently trades at ¥13.58, while our model-based Fair Value estimate is ¥10.57, implying the stock looks roughly 22.2% overvalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, LBX Pharmacy Chain Joint Stock Company generated revenue of 22.3B CNY at a net margin of 1.8%. Revenue grew 0.8% year over year. It earns a return on equity of 7.6%. Net debt stands at 8.0B CNY. Fundamentals as of Aug 13, 2026
Our scenario range runs from ¥7.92 (bear case) to ¥13.21 (bull case); at ¥13.58, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 39% below its 52-week high and 18% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -22%, 603883 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥51.60) versus Dividend Discount (¥4.48). Highest evidence: Growth DCF (80).
Notify me when 603883 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
LBX Pharmacy Chain Joint Stock Company operates a chain of pharmacy stores in Mainland China. The company operates through three segments: Retail business, Wholesale business, and Other.
Full company description
LBX Pharmacy Chain Joint Stock Company operates a chain of pharmacy stores in Mainland China. The company operates through three segments: Retail business, Wholesale business, and Other. It engages in commodity retail and wholesale business; and pharmaceutical manufacturing business and others, as well as sells drugs, and other health and beauty-related products through its marketing network. The company is also involved in wholesale and retail of pharmaceutical products; Chinese medicine research and development; E-commerce; food and department store retail; commodity wholesale; and retail of maternal and infant products. In addition, it provides business, information technology consulting, technical, pharmaceutical consulting, clinic, and medical services. The company was formerly known as Laobaixing Pharmacy Chain Joint Stock Company. LBX Pharmacy Chain Joint Stock Company was founded in 2001 and is headquartered in Changsha, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
LBX Pharmacy Chain Joint Stock Company reported revenue of ¥22.2B in FY2025 versus ¥15.7B in FY2021, a compound +9.1%/yr. Reported net income was ¥382M in FY2025, compounding −13.1%/yr from FY2021.
of which total revenue +20.8 pp · buybacks/dilution −7.5 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
603883 screens 22% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 63 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$38.86 | HK$33.31 | -14% |
| Raia Drogasil S.A RADL3 | R$18.00 | R$15.58 | -13% |
| Alibaba Health Information Technology Limited 0241 | HK$3.33 | HK$2.04 | -39% |
| Yifeng Pharmacy Chain Co 603939 | ¥24.03 | ¥29.07 | +21% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.14 | ¥23.86 | +32% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 726.02 MXN | +57% |
| MedPlus Health Services Limited MEDPLUS | ₹675.05 | ₹379.25 | -44% |
| Yixintang Pharmaceutical Group 002727 | ¥12.29 | ¥9.45 | -23% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥16.51 | ¥10.05 | -39% |
| ShuYu Civilian Pharmacy Corp 301017 | ¥13.86 | ¥5.91 | -57% |
Compare LBX Pharmacy Chain Joint Stock Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is LBX Pharmacy Chain Joint Stock Company (603883) overvalued or undervalued?
What is the fair value of 603883?
What is the quality score of 603883?
What is the revenue of LBX Pharmacy Chain Joint Stock Company (603883)?
What is the net profit margin of 603883?
Does LBX Pharmacy Chain Joint Stock Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track LBX Pharmacy Chain Joint Stock Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.